Our findings address a critical challenge in treating KAT6A-rearranged AML, a high-risk subtype with poor prognosis [7], by highlighting the therapeutic potential of targeting BPTF and CBP/P300 activity. The gene discussed is EP300; the disease is acute myeloid leukemia.